INTRODUCTION
Isotretinoin, or 13-cis retinoic acid, is the treatment of choice for severe recalcitrant nodular acne, and has been used to treat various other skin disorders, such as severe recalcitrant psoriasis, for almost two decades [1] . This drug has numerous ocular side effects, including abnormal meibomian gland secretions, blepharoconjunctivitis, corneal opacities, decreased dark adaptation, decreased tolerance to contact lens use, decreased vision, increased tear osmolarity, keratitis, meibomian gland atrophy, myopia, ocular discomfort, dry eyes, photophobia, and teratogenic ocular abnormalities [2] [3] [4] .
Previous reports have suggested a causal association between oral isotretinoin and acquired central nervous system (CNS) neurotoxicity and neuropathy [5] [6] [7] . The most frequent CNS adverse effect associated with oral isotretinoin is headache, either as an independent adverse effect or as part of benign intracranial hypertension, which is additionally characterized by nausea and visual changes [5] [6] [7] . A single case of optic swelling associated with isotretinoin has also been reported [8] .
Retinal ganglion cells contain melanopsin, which is very similar to other opsin photopigments, and it is known that melanopsin uses the same retinaldehyde chromophore. Therefore, isotretinoin may exert an inhibitory effect on chromophore regeneration in retinal ganglion cells similar to what is seen in rod and cone cells [9] . However, to the best of the authors' knowledge, this is the first study that objectively determines retinal nerve fiber layer (RNFL) thickness changes after 6 months of oral isotretinoin treatment.
MATERIALS AND METHODS
Patients prescribed typical oral isotretinoin (0.5 mg/kg) to treat nodulocystic acne were referred by dermatologists for a detailed ophthalmologic examination. Informed consent and ethical approval was given by patients. isotretinoin both clinically and with visual field tests, and reported no significant change after 5.5 months. In a pivotal study by Weleber et al. [4] , three of 50 patients treated with isotretinoin (1 mg/kg/day) for cystic acne complained of poor night vision and/or excessive glare sensitivity. While still receiving the drug or shortly thereafter, two patients were found to have abnormal dark-adaptation curves, with elevations of either cone or rod thresholds, or both. Six months following cessation of therapy, the electroretinograph was still abnormal for one patient, but continued improvement was evident at 25 months; for the second patient, the electroretinograph was normal at 1 year.
Nyctalopia, or night blindness, has been reported with isotretinoin use [20] . This has been associated with objectively abnormal scotopic electroretinograms. It has been postulated that competitive inhibition of ocular retinol dehydrogenase by isotretinoin may be the cause of the nyctalopia [21, 22] . None of the patients in this study developed nyctalopia after 6 months of treatment.
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In the present study, the authors did not find any color vision disturbances. Color vision is a sensitive indicator of optic nerve dysfunction. It is reduced in retinal and optic nerve disorders.
Fraunfelder et al. [2] first suggested an association between isotretinoin and reversible decreased color vision.
There are limitations of this study that must be addressed. First, the authors did not perform any electrophysiological studies. In a recent study, an increased latency of P100 wave was detected after therapy in 18% of patients treated orally with isotretinoin [10] . Although this result was not statistically significant, subclinical effects of isotretinoin on optic nerve functions, which can be detected electrophysiologically before anatomical signs occur, may be possible.
In addition, assessment of pupillary functions without using pupillography was another limitation of the present study.
CONCLUSION
In conclusion, the authors did not find any adverse effects of systemic isotretinoin treatment on RNFL thickness. Nevertheless, the authors think that the assessment of these functions in a larger patient group and with additional tests for early detection of visual field loss, such as Short Wavelength Automated Perimetry (SWAP) or Frequency Doubling Technology (FDT), would be more appropriate.
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